차세대 시퀀싱 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 제품별, 용도별, 워크플로우별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Next Generation Sequencing Market Growth & Trends:

The global next generation sequencing market size is expected to reach USD 31.26 billion by 2030, registering a CAGR of 21.12% from 2024 to 2030, according to a new report by Grand View Research, Inc. Next-generation Sequencing (NGS) is a parallel processing technique that can establish the sequence of nucleotides in a whole genome with scalability, ultra-high capacity, and fast speed. Furthermore, in the healthcare industry, NGS is gradually being incorporated into medical laboratory research, screening, and disease diagnoses. In personalized medicine, it has been frequently utilized to accelerate the drug research process.

Different potential sequencing methods such as RNA sequencing, whole-genome sequencing, and whole-exome and targeted sequencing amongst others are prominently used by researchers to get comprehensive sample analysis. When compared to the traditional Sanger sequencing technology, NGS is less expensive and provides higher throughput for DNA sequencing. The growing automation in the pre-sequencing protocols, post-sequencing protocols, and data analysis is also projected to have a positive impact on the NGS market. The utilization of novel platforms for the development of personalized medicine by medical analysis at a genetic level is also a significant factor, which is expected to enhance demand for NGS over the forecast period.

Besides, there are other significant growth trends that are being witnessed in the sequencing industry, such as the development of personalized medicine and companion diagnostics, growing advancements in cloud computing, and data integration. Furthermore, the easy availability of genomic and proteomic data has poised this market to exhibit potentially high-value avenues and opportunities for growth over the forecast period. The market growth is also being fueled by an increase in the global prevalence of cancer and the availability of sophisticated healthcare facilities. As per GLOBOCAN 2020, there have been 1,92,92,789 new cancer cases in 2020, with the number expected to rise to 2,88,87,940 by 2040. Such a substantial rise in the number of cancer cases is estimated to leverage cancer research which will eventually accelerate the NGS market growth.

The NGS diagnostic techniques have the potential to determine a virus's genomic sequence and aid scientists in their understanding of mutations. Furthermore, throughout the COVID-19 epidemic, governments across the globe have been collaborating with the corporate sector to introduce NGS technology to the market as a viable diagnostic tool. The US Food and Drug Administration granted Illumina Inc. a case of emergency use permit for the first COVID-19 diagnostic using the next-generation sequence technique in June 2020. The Illumina COVIDSeq Test for qualitative identification of SARS-CoV-2 RNA has been approved by the FDA. As a result, the usage of next-generation sequencing (NGS) technologies is projected to increase during the pandemic.

Next Generation Sequencing Market Report Highlights:

• By application, the oncology segment held the largest revenue share of 27.31% in 2023. The segment growth is prominently attributed to increasing in the prevalence of cancer and advancements in sequencing technologies
• The academic research segment is expected to grow lucratively over the forecast period due to an increase in application-based usage in these institutes and a rise in oncology research. In addition, advancements in R&D for therapeutics, oncology, and genomics research led to the growth of the market
• In Asia Pacific, the market is expected to grow considerably during the forecast period owing to extensive developments in healthcare infrastructure, the positive approach of respective countries for adoption of advanced technologies, and the presence of key players
• North America dominated the market with a share of 49.35% in 2023, due to the presence of high R&D investment, and availability of technologically advanced healthcare research framework, the development of WGS in the region is also expected to serve as a critical factor for the growth of the North America NGS market throughout the forecast period

Table of Contents

Chapter 1 Methodology And Scope

• 1.1 Research Scope
  • 1.1.1 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Primary Research
  • 1.3.4 Details Of Primary Research
    • 1.3.4.1 Primary Interviews: Statistics
    • 1.3.4.1.1 Geographical Distribution Of Primary Interviews
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Objectives
  • 1.6.1 Objective 1
  • 1.6.2 Objective 2

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Market Variables, Trends & Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
  • 3.1.2 Related/Ancillary Market Outlook
• 3.2 Cost Structure Analysis
• 3.3 User Perspective Analysis
  • 3.3.1 Consumer Behavior Analysis
    • 3.3.1.1 Market Influencer Analysis
• 3.4 Procedure Cost Analysis
• 3.5 List Of Key End Users
  • 3.5.1 By Type
  • 3.5.2 By Product
  • 3.5.3 By U.S. State
• 3.6 Technology Overview
  • 3.6.1 Technology Timeline
• 3.7 Impact Of Covid-19 Pandemic
  • 3.7.1 Impact On The Supply Chain
  • 3.7.2 Association Of Covid-19 With Ngs
• 3.8 Market Trends And Outlook
• 3.9 Market Segmentation And Scope
• 3.10 Market Dynamics
  • 3.10.1 Market Driver Analysis
    • 3.10.1.1 Exponentially Decreasing Costs For Genetic Sequencing
    • 3.10.1.2 Development Of Companion Diagnostics And Personalized Medicine
    • 3.10.1.3 Rise In Competition Among Prominent Market Entities
    • 3.10.1.4 Rising Clinical Opportunity For Ngs Technology
    • 3.10.1.5 Technological Advancements In Cloud Computing And Data Integration
    • 3.10.1.6 Growing Healthcare Expenditure Supporting Development Of Effective Diagnostic & Therapeutic Procedures For Cancer
    • 3.10.1.7 Increasing Prevalence Of Cancer
  • 3.10.2 Market Restraint Analysis
    • 3.10.2.1 Lack Of Computational Efficiency For Data Management
    • 3.10.2.2 Non-Value-Based Ngs Reimbursement Policy And Regulation Status
    • 3.10.2.3 Challenges Associated With Ngs Implementation
• 3.11 Business Environment Analysis
  • 3.11.1 Swot Analysis; By Factor (Political & Legal, Economic, And Technological)
  • 3.11.2 Porter's Five Forces Analysis
• 3.12 Major Deals And Strategic Alliances Analysis
  • 3.12.1 Joint Ventures
  • 3.12.2 Mergers & Acquisitions
  • 3.12.3 Licensing & Partnerships
  • 3.12.4 Technology Collaborations

Chapter 4 Technology Business Analysis

• 4.1 Next Generation Sequencing Market: Technology Movement Analysis
• 4.2 Targeted Sequencing & Resequencing
  • 4.2.1 Targeted Sequencing & Resequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.2.1.1 Dna-Based Targeted Sequencing & Resequencing
    • 4.2.1.1.1 Dna-Based Targeted Sequencing & Resequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.2.1.2 Rna-Based Targeted Sequencing & Resequencing
    • 4.2.1.2.1 Rna -Based Targeted Sequencing & Resequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.3 Whole Genome Sequencing
  • 4.3.1 Whole Genome Sequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.4 Whole Exome Sequencing
  • 4.4.1 Whole Exome Sequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.5 Others
  • 4.5.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Product Business Analysis

• 5.1 Next Generation Sequencing Market: Product Movement Analysis
• 5.2 Platforms
  • 5.2.1 Platforms Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.2.1.1 Sequencing
    • 5.2.1.1.1 Sequencing Platforms Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.2.1.2 Data Analysis
    • 5.2.1.2.1 Data Analysis Platforms Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.3 Consumables
  • 5.3.1 Consumables Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.3.2 Sample Preparation
    • 5.3.2.1 Sample Preparation Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.3.3 Target Enrichment
    • 5.3.3.1 Target Enrichment Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.3.4 Others
    • 5.3.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Application Business Analysis

• 6.1 Next Generation Sequencing Market: Application Movement Analysis
• 6.2 Oncology
  • 6.2.1 Oncology Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.2.2 Diagnostics & Screening
    • 6.2.2.1 Diagnostics & Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.2.2 Oncology Screening
    • 6.2.2.2.1 Oncology Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.2.2.2 Sporadic Cancer Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.2.2.3 Inherited Cancer Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.2.3 Companion Diagnostics
    • 6.2.2.3.1 Companion Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.2.4 Other Diagnostics
    • 6.2.2.4.1 Other Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.2.3 Research Studies
    • 6.2.3.1 Research Studies Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.3 Clinical Investigation
  • 6.3.1 Clinical Investigation Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.3.2 Infectious Diseases
    • 6.3.2.1 Infectious Diseases Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.3.3 Idiopathic Diseases
    • 6.3.3.1 Idiopathic Diseases Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.3.4 Inherited Diseases
    • 6.3.4.1 Inherited Diseases Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.3.5 Non-Communicable/Other Diseases
    • 6.3.5.1 Non-Communicable/Other Diseases Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.4 Reproductive Health
  • 6.4.1 Reproductive Health Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.4.2 Nipt
    • 6.4.2.1 Nipt Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.4.2.2 Aneuploidy
    • 6.4.2.2.1 Aneuploidy Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.4.2.3 Microdeletions
    • 6.4.2.3.1 Microdeletions Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.4.3 Pgt
    • 6.4.3.1 Pgt Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.4.4 Newborn Genetic Screening
    • 6.4.4.1 Newborn Genetic Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.4.5 Single Gene Analysis
    • 6.4.5.1 Single Gene Analysis Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.5 Hla Typing/Immune System Monitoring
  • 6.5.1 Hla Typing/Immune System Monitoring Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.6 Metagenomics, Epidemiology & Drug Development
  • 6.6.1 Metagenomics, Epidemiology & Drug Development Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.7 Agrigenomics & Forensics
  • 6.7.1 Agrigenomics & Forensics Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.8 Consumer Genomics
  • 6.8.1 Consumer Genomics Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Workflow Business Analysis

• 7.1 Next Generation Sequencing Market: Workflow Movement Analysis
• 7.2 Presequencing
  • 7.2.1 Pre-Sequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.1.1 Ngs Library Preparation Kits
    • 7.2.1.1.1 Ngs Library Preparation Kits Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.1.2 Semiautomated Library Preparation
    • 7.2.1.2.1 Semiautomated Library Preparation Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.1.3 Automated Library Preparation
    • 7.2.1.3.1 Automated Library Preparation Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.3 Sequencing
  • 7.3.1 Sequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.4 Data Analysis
  • 7.4.1 Data Analysis Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.4.2 Primary Data Ngs Analysis
    • 7.4.2.1 Primary Data Analysis Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.4.3 Secondary Data Analysis
    • 7.4.3.1 Secondary Data Analysis Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.4.4 Tertiary Data Analysis
    • 7.4.4.1 Tertiary Data Analysis Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 End-Use Business Analysis

• 8.1 Next Generation Sequencing Market: End-Use Movement Analysis
• 8.2 Academic Research
  • 8.2.1 Academic Research Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.3 Clinical Research
  • 8.3.1 Clinical Research Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.4 Hospitals & Clinics
  • 8.4.1 Hospitals & Clinics Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.5 Pharmaceutical & Biotech Entities
  • 8.5.1 Pharmaceutical & Biotech Entities Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.6 Other Users
  • 8.6.1 Other Users Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9 Next Generation Sequencing Market: Regional Estimates And Trend Analysis, By Product, Technology, Application, Workflow, & End-Use

• 9.1 North America
  • 9.1.1 North America Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.1.2 U.S.
    • 9.1.2.1 Key Country Dynamics
    • 9.1.2.2 Target Disease Prevalence
    • 9.1.2.3 Competitive Scenario
    • 9.1.2.4 Regulatory Framework
    • 9.1.2.5 Reimbursement Scenario
    • 9.1.2.6 U.S. Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.1.3 Canada
    • 9.1.3.1 Key Country Dynamics
    • 9.1.3.2 Target Disease Prevalence
    • 9.1.3.3 Competitive Scenario
    • 9.1.3.4 Regulatory Framework
    • 9.1.3.5 Reimbursement Scenario
    • 9.1.3.6 Canada Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 9.2 Europe
  • 9.2.1 Europe Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.2.2 Uk
    • 9.2.2.1 Key Country Dynamics
    • 9.2.2.2 Target Disease Prevalence
    • 9.2.2.3 Competitive Scenario
    • 9.2.2.4 Regulatory Framework
    • 9.2.2.5 Reimbursement Scenario
    • 9.2.2.6 Uk Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.2.3 Germany
    • 9.2.3.1 Key Country Dynamics
    • 9.2.3.2 Target Disease Prevalence
    • 9.2.3.3 Competitive Scenario
    • 9.2.3.4 Regulatory Framework
    • 9.2.3.5 Reimbursement Scenario
    • 9.2.3.6 Germany Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.2.4 France
    • 9.2.4.1 Key Country Dynamics
    • 9.2.4.2 Target Disease Prevalence
    • 9.2.4.3 Competitive Scenario
    • 9.2.4.4 Regulatory Framework
    • 9.2.4.5 Reimbursement Scenario
    • 9.2.4.6 France Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.2.5 Spain
    • 9.2.5.1 Key Country Dynamics
    • 9.2.5.2 Competitive Scenario
    • 9.2.5.3 Regulatory Framework
    • 9.2.5.4 Reimbursement Scenario
    • 9.2.5.5 Spain Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.2.6 Italy
    • 9.2.6.1 Key Country Dynamics
    • 9.2.6.2 Target Disease Prevalence
    • 9.2.6.3 Competitive Scenario
    • 9.2.6.4 Regulatory Framework
    • 9.2.6.5 Reimbursement Scenario
    • 9.2.6.6 Italy Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.2.7 Denmark
    • 9.2.7.1 Key Country Dynamics
    • 9.2.7.2 Target Disease Prevalence
    • 9.2.7.3 Competitive Scenario
    • 9.2.7.4 Regulatory Framework
    • 9.2.7.5 Reimbursement Scenario
    • 9.2.7.6 Denmark Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.2.8 Sweden
    • 9.2.8.1 Key Country Dynamics
    • 9.2.8.2 Target Disease Prevalence
    • 9.2.8.3 Competitive Scenario
    • 9.2.8.4 Regulatory Framework
    • 9.2.8.5 Reimbursement Scenario
    • 9.2.8.6 Sweden Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.2.9 Norway
    • 9.2.9.1 Key Country Dynamics
    • 9.2.9.2 Target Disease Prevalence
    • 9.2.9.3 Competitive Scenario
    • 9.2.9.4 Regulatory Framework
    • 9.2.9.5 Reimbursement Scenario
    • 9.2.9.6 Norway Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 9.3 Asia Pacific
  • 9.3.1 Asia Pacific Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.3.2 Japan
    • 9.3.2.1 Key Country Dynamics
    • 9.3.2.2 Target Disease Prevalence
    • 9.3.2.3 Competitive Scenario
    • 9.3.2.4 Regulatory Framework
    • 9.3.2.5 Reimbursement Scenario
    • 9.3.2.6 Japan Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.3.3 China
    • 9.3.3.1 Key Country Dynamics
    • 9.3.3.2 Target Disease Prevalence
    • 9.3.3.3 Competitive Scenario
    • 9.3.3.4 Regulatory Framework
    • 9.3.3.5 Reimbursement Scenario
    • 9.3.3.6 China Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.3.4 India
    • 9.3.4.1 Key Country Dynamics
    • 9.3.4.2 Target Disease Prevalence
    • 9.3.4.3 Competitive Scenario
    • 9.3.4.4 Regulatory Framework
    • 9.3.4.5 Reimbursement Scenario
    • 9.3.4.6 India Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.3.5 Australia
    • 9.3.5.1 Key Country Dynamics
    • 9.3.5.2 Target Disease Prevalence
    • 9.3.5.3 Competitive Scenario
    • 9.3.5.4 Regulatory Framework
    • 9.3.5.5 Reimbursement Scenario
    • 9.3.5.6 Australia Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.3.6 Thailand
    • 9.3.6.1 Key Country Dynamics
    • 9.3.6.2 Target Disease Prevalence
    • 9.3.6.3 Competitive Scenario
    • 9.3.6.4 Regulatory Framework
    • 9.3.6.5 Reimbursement Scenario
    • 9.3.6.6 Thailand Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.3.7 South Korea
    • 9.3.7.1 Key Country Dynamics
    • 9.3.7.2 Target Disease Prevalence
    • 9.3.7.3 Competitive Scenario
    • 9.3.7.4 Regulatory Framework
    • 9.3.7.5 Reimbursement Scenario
    • 9.3.7.6 South Korea Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 9.4 Latin America
  • 9.4.1 Latin America Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.4.2 Brazil
    • 9.4.2.1 Key Country Dynamics
    • 9.4.2.2 Target Disease Prevalence
    • 9.4.2.3 Competitive Scenario
    • 9.4.2.4 Regulatory Framework
    • 9.4.2.5 Reimbursement Scenario
    • 9.4.2.6 Brazil Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.4.3 Mexico
    • 9.4.3.1 Key Country Dynamics
    • 9.4.3.2 Target Disease Prevalence
    • 9.4.3.3 Competitive Scenario
    • 9.4.3.4 Regulatory Framework
    • 9.4.3.5 Reimbursement Scenario
    • 9.4.3.6 Mexico Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.4.4 Argentina
    • 9.4.4.1 Key Country Dynamics
    • 9.4.4.2 Target Disease Prevalence
    • 9.4.4.3 Regulatory Framework
    • 9.4.4.4 Reimbursement Scenario
    • 9.4.4.5 Argentina Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 9.5 MEA
  • 9.5.1 MEA Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.2 South Africa
    • 9.5.2.1 Key Country Dynamics
    • 9.5.2.2 Target Disease Prevalence
    • 9.5.2.3 Competitive Scenario
    • 9.5.2.4 Regulatory Framework
    • 9.5.2.5 Reimbursement Scenario
    • 9.5.2.6 South Africa Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.3 Saudi Arabia
    • 9.5.3.1 Key Country Dynamics
    • 9.5.3.2 Target Disease Prevalence
    • 9.5.3.3 Competitive Scenario
    • 9.5.3.4 Regulatory Framework
    • 9.5.3.5 Reimbursement Scenario
    • 9.5.3.6 Saudi Arabia Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.4 UAE
    • 9.5.4.1 Key Country Dynamics
    • 9.5.4.2 Target Disease Prevalence
    • 9.5.4.3 Competitive Scenario
    • 9.5.4.4 Regulatory Framework
    • 9.5.4.5 Reimbursement Scenario
    • 9.5.4.6 UAE Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.5 Kuwait
    • 9.5.5.1 Key Country Dynamics
    • 9.5.5.2 Target Disease Prevalence
    • 9.5.5.3 Competitive Scenario
    • 9.5.5.4 Regulatory Framework
    • 9.5.5.5 Reimbursement Scenario
    • 9.5.5.6 Kuwait Ngs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 10 Competitive Landscape

• 10.1 Company Categorization
• 10.2 Strategy Mapping
• 10.3 Company Market Share Analysis, 2023
• 10.4 Company Profiles
  • 10.4.1 Thermo Fisher Scientific, Inc.
    • 10.4.1.1 Company Overview
    • 10.4.1.2 Life Technologies Corporation
    • 10.4.1.2.1 Company Overview
    • 10.4.1.3 Financial Performance
    • 10.4.1.4 Product Benchmarking
    • 10.4.1.5 Strategic Initiatives
  • 10.4.2 Qiagen N.V.
    • 10.4.2.1 Company Overview
    • 10.4.2.2 Clc Bio
    • 10.4.2.2.1 Company Overview
    • 10.4.2.3 Financial Performance
    • 10.4.2.4 Product Benchmarking
    • 10.4.2.5 Strategic Initiatives
  • 10.4.3 Illumina, Inc.
    • 10.4.3.1 Company Overview
    • 10.4.3.2 Edico Genome
    • 10.4.3.2.1 Company Overview
    • 10.4.3.3 Financial Performance
    • 10.4.3.4 Product Benchmarking
    • 10.4.3.5 Strategic Initiatives
  • 10.4.4 F. Hoffmann-La Roche Ag
    • 10.4.4.1 Company Overview
    • 10.4.4.2 Foundation Medicine
    • 10.4.4.2.1 Company Overview
    • 10.4.4.3 Financial Performance
    • 10.4.4.4 Product Benchmarking
    • 10.4.4.5 Strategic Initiatives
  • 10.4.5 Agilent Technologies, Inc.
    • 10.4.5.1 Company Overview
    • 10.4.5.2 Financial Performance
    • 10.4.5.3 Product Benchmarking
    • 10.4.5.4 Strategic Initiatives
  • 10.4.6 Bio-Rad Laboratories, Inc.
    • 10.4.6.1 Company Overview
    • 10.4.6.2 Gnubio
    • 10.4.6.2.1 Company Overview
    • 10.4.6.3 Financial Performance
    • 10.4.6.4 Product Benchmarking
    • 10.4.6.5 Strategic Initiatives
  • 10.4.7 Pieriandx
    • 10.4.7.1 Company Overview
    • 10.4.7.2 Tute Genomics
    • 10.4.7.2.1 Company Overview
    • 10.4.7.2.2 Knome, Inc.
    • 10.4.7.2.2.1 Company Overview
    • 10.4.7.3 Product Benchmarking
    • 10.4.7.4 Strategic Initiatives
  • 10.4.8 Oxford Nanopore Technologies Plc
    • 10.4.8.1 Company Overview
    • 10.4.8.2 Financial Performance
    • 10.4.8.3 Product Benchmarking
    • 10.4.8.4 Strategic Initiatives
  • 10.4.9 Partek Incorporated
    • 10.4.9.1 Company Overview
    • 10.4.9.2 Product Benchmarking
    • 10.4.9.3 Strategic Initiatives
  • 10.4.10 Eurofins Scientific
    • 10.4.10.1 Company Overview
    • 10.4.10.2 Eurofins Gatc Biotech Gmbh
    • 10.4.10.2.1 Company Overview
    • 10.4.10.3 Financial Performance
    • 10.4.10.4 Product Benchmarking
    • 10.4.10.5 Strategic Initiatives
  • 10.4.11 Dnastar
    • 10.4.11.1 Company Overview
    • 10.4.11.2 Product Benchmarking
    • 10.4.11.3 Strategic Initiatives
  • 10.4.12 Sophia Genetics.
    • 10.4.12.1 Company Overview
    • 10.4.12.2 Financial Performance
    • 10.4.12.3 Product Benchmarking
    • 10.4.12.4 Strategic Initiatives
  • 10.4.13 Fabric Genomics, Inc.
    • 10.4.13.1 Company Overview
    • 10.4.13.2 Financial Performance
    • 10.4.13.3 Product Benchmarking
    • 10.4.13.4 Strategic Initiatives
  • 10.4.14 Laboratory Corporation Of America
    • 10.4.14.1 Company Overview
    • 10.4.14.2 Financial Performance
    • 10.4.14.3 Product Benchmarking
    • 10.4.14.4 Strategic Initiatives
  • 10.4.15 Syapse, Inc.
    • 10.4.15.1 Company Overview
    • 10.4.15.2 Product Benchmarking
    • 10.4.15.3 Strategic Initiatives
  • 10.4.16 Personalis, Inc.
    • 10.4.16.1 Company Overview
    • 10.4.16.2 Financial Performance
    • 10.4.16.3 Product Benchmarking
    • 10.4.16.4 Strategic Initiatives
  • 10.4.17 10x Genomics
    • 10.4.17.1 Company Overview
    • 10.4.17.2 Financial Performance
    • 10.4.17.3 Product Benchmarking
    • 10.4.17.4 Strategic Initiatives
  • 10.4.18 Dnanexus, Inc.
    • 10.4.18.1 Company Overview
    • 10.4.18.2 Product Benchmarking
    • 10.4.18.3 Strategic Initiatives
  • 10.4.19 Centogene N.V.
    • 10.4.19.1 Company Overview
    • 10.4.19.2 Financial Performance
    • 10.4.19.3 Product Benchmarking
    • 10.4.19.4 Strategic Initiatives
  • 10.4.20 Invitae Corporation
    • 10.4.20.1 Company Overview
    • 10.4.20.2 Financial Performance
    • 10.4.20.3 Product Benchmarking
    • 10.4.20.4 Strategic Initiatives
  • 10.4.21 Genedx, Llc
    • 10.4.21.1 Company Overview
    • 10.4.21.2 Financial Performance
    • 10.4.21.3 Product Benchmarking
    • 10.4.21.4 Strategic Initiatives